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Introduction 
Heparin was discovered by two independent
researchers:  Doyon in 1911 and McLean in 1916 year.
Doyon detected an anticoagulant produced in the liver,
later called antithrombin. In 1916 year, Mc Lean, con-
ducting studies on canine livers, found a compound
stimulating the activity of antithrombin, so called
heparin that turned out to be an extremely valuable
medication. It was used in the prophylaxis of throm-
boembolic diseases in patients who underwent opera-
tions, orthopedic or gynecological procedures, as well
as in hemodialysis and many others. 
Wide administration of heparin increased the inter-
est in its systemic activity, especially, in its modulator
effect on endothelial cells (EC).  However, despite
many years of studies, side effects of heparin as well
as its influence on the endothelium have not been
explained completely. The studies on the endothelial
cell culture (HUVEC; human umbilical vein endothe-
lial cells) seem to be of great importance. They enable
a better understanding of the processes taking place
during heparin administration. 
Heparins, as glycosaminoglycans, form chains built
up of repeated disaccharide unites. Each such a unit is
formed via binding of glucosamine with glucuronic
acid.
Heparins are divided into long-chained, e.g. unfrac-
tionated heparin (UFH) and short-chained, e.g. low-
molecular weight heparins (LMWHs), depending on
the number of polysaccharide chains. There are
numerous differences between these two types of
heparins regarding dissimilarities in the mechanism of
their activity, pharmacokinetics and complications
after therapy.    
Comparison of basic features of unfractionat-
ed and low-molecular weight heparins 
The anticoagulant activity of heparin includes its bind-
ing with antithrombin (AT), due to which a slow-act-
ing compound is transformed into a fast inhibitor of
thrombin (factor IIa) and factor Xa. A three-part com-
plex is formed on AT, heparin and inhibited coagula-
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tion enzyme. Afterwards, heparin disconnects and can
be used again. It inactivates, to a lower degree, other
serine proteases such as factors VIIa, IXa, XIa and XII.
Another mechanism of heparin activity consists in
releasing the inhibitor of an extrinsic coagulation path-
way via a tissue factor (TFPI; Tissue Factor Pathway
Inhibitor) from the endothelial surface [1]. Polysac-
charide chains include pentasaccharide structures that
binds heparin with AT by means of the glucosamine
radical, intensifying its activity at the same time. The
presence of pentasaccharide sequence in the chain
enables binding with antithrombin. However, not all
molecules show this ability, because chains without
pentasaccharide present no anticoagulant activity.
Molecules, built up of 18 or more saccharide residues,
except for pentasaccharide indispensable to bind AT,
possess abilities to inhibit the activity of thrombin.
Shorter chains are able to neutralize only factor Xa. At
the beginning, heparins with longer chains were syn-
thesized, making it possible, in the comparable degree,
to inhibit the activity of factors Xa and IIa. These com-
pounds were called unfractionated heparins of medium
molecular weight of 12-15 kDa. UFH is obtained from
the mucosa of pig's intestines or ox's lungs.
Despite the lack of heparin toxicity, many compli-
cations, e.g., hemorrhage or thrombocytopenia may be
reported during its application. This fact has caused the
research of better anticoagulant agents without side
effects. Shortening of polysaccharide chains of heparin
via chemical or enzymatic depolymerization and purifi-
cation has given interesting results. Fractioned heparins,
popularly called low-molecular weight heparins, with
medium molecular weight of 3.9-6 kDa were obtained
in this way [2]. Additionally, these heparins differ with
regard to pharmacokinetics, bioaccessibility and many
other features (Table 1). Lower binding of LMWHs
with plasma proteins than it is observed in case of UFH,
plays a major role in their biological accessibility
increase.  In case of UFH, a medium period of half-life
equals 90 minutes, whereas for LMWHs it amounts
from 2 to 3 hours after intravenous administration,
which entails pharmacokinetic differences as well.
LMWHs are also characterized by lower binding with
endothelium that was confirmed in a cell culture.
Significant profits of LMWHs result from fewer
hemorrhages than during UFH administration.  This
enabled partial elimination of the most serious com-
plication of heparin therapy. A decrease in hemor-
rhage frequency can be explained by lower affinity of
LMWHs to the von Willebrand factor (vWF), which
is associated with its normal function in the process
of coagulation, mainly consisting in platelet adhesion
and factor VIII protection. The next reason for hem-
orrhage after UFH is an increase in permeability of
blood vessels, whereas administration of LMWHs
has no such effect. LMWHs, in comparison with
UFH, are characterized by less influence on platelet
activity which is proved by significantly less frequent
thrombocytopenia. Postheparin thrombocytopenia
may occur due to two processes. One of them is non-
immunological (HAT; heparin-associated thrombo-
cytopenia), which is the most frequent mild form of
thrombocytopenia, without sever clinical symptoms.
The other mechanism (HIT; heparin-induced throm-
bocytopenia), is a severe complication of high mor-
tality. It occurs when antibodies against platelet fac-
tor 4 (PF4), mainly from IgG class, form complexes
with heparin and activate platelets. Low-molecular
weight heparins as medications affecting platelets to
a lesser extent, have only partially met expectations,
though HIT cases are significantly less frequent after
their administration [3].
In the face of suspicion of heparins' different
effects on endothelium, only the usage of cell culture
techniques has explained and confirmed earlier specu-
lations. The comparison of UFH and LMWHs activity
in HUVEC, with special regard to differences in
haemostatic, antiangiogenic or anticancerous features,
has become of great interest.
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Fig. 1.  Disaccharide unit repeating itself  n-times (depending on
the type of heparin) in polysaccharide chains. 
Table 1. Comparison of unfractioned and low molecular heparins
(according to Chojnowski 2000, Windyga 2003 modified).
Abbreviations: HRGP – glycoprotein rich in histidine , Fn – fibronectin,
Vn – vitronectin, PF4 – platelet factor 4, vWF – von Willebrand factor 
Influence of UFH vs LMWHs on haemostatic
factors in HUVEC culture 
Endothelium takes a vital part in the variety of mecha-
nisms such as release of many substances engaged in
e.g., pro/anticoagulant balance, angiogenesis as well
as inflammatory and immunological processes. Dam-
age to its structure leads to disturbance of multi-organ-
ic cooperation that result in numerous pathological
changes, such as thrombosis, atherosclerosis and
hypertension. There is a layer of glycocalix built up of
glycosaminoglycans (GAG), where heparin sulphate
predominates. Endothelium, charged negatively by
means of glycocalix, pushes away blood morphogenic
components [5]. The role of endothelial cells in
haemostasis is to inhibit blood coagulation, which is
connected with anticoagulant factors. Antithrombin is,
undoubtedly, the most important anticoagulant factor
of all produced by endothelium, whereas surface
GAGs (heparin-like particles) significantly enhance its
activity. Exogenous heparin acts like particles forming
glycocalix and its administration influences the fea-
tures of the vascular wall. Endothelial cells release
also other substances playing a pivotal role in the
maintenance of blood flow, such as TFPI, a tissue –
type plasminogen activator (t-PA), and thrombomod-
ulin (TM). The activation of TM takes place in the
presence of its cofactor – protein S, causing degrada-
tion and inactivation of active factors VIII and V.
Additionally, protein C shows profibrinolytic proper-
ties via binding of plasminogen activator inhibitor-1
(PAI-1). Heparins can bind vWF and PF4, inhibiting
aggregation and activation of platelets. The further
studies, confirming and widening former data, were
carried out using HUVEC culture. Apart from the anti-
coagulant activity, there is a procoagulant aspect of
heparin's impact on EC – releasing procoagulant fac-
tors e.g. tissue factor (TF) or plasminogen activator
inhibitor-1 (PAI-1).
The length of polysaccharide chains is of great
importance in haemostatic balance. The studies per-
formed on HUVEC culture confirmed the earlier find-
ings regarding the stimulating activity of heparin on
TF release [6]. An outstandingly high level of TF anti-
gen, regardless a dose, was observed in the test with
UFH.  In case of LMWHs, the highest increase was
observed after 24-hour stimulation with bemiparin and
was similar to that reported in control culture – with-
out stimulation. The excessive release of TF may
results from the markedly stronger activation of its sur-
face during UFH application. Hence, LMWHs admin-
istration seems to be markedly more profitable [6].
Salez et al. [7] obtained opposite results after stimula-
tion of endothelial cells with UFH and observed no
significant changes in TF concentration regardless the
incubation time. However, administration of enoxa-
parin had similar effects to the stimulation with bemi-
parin. Interestingly, heparins decrease the enhanced
activity of antigen as well as mRNA TF expression
after stimulation of endothelial cells with lipopolisac-
charide (LPS). These tests were carried out in two dif-
ferent types of endothelial cell cultures: human
microvascular (HMEC-1) and macrovascular
(HUVEC) endothelial cells. Neutralization of the
enhanced TF level by means of LPS in HMEC-1 was
the most efficient in case of dalteparin.  In HUVEC,
dalteparin and UFH inhibited similarly TF activity,
antigen as well as mRNA expression. These results
refer to the short time (about 4 hours) of heparin
administration, whereas, in case of longer stimulation
(24 hours), the effects of TF inhibition were compara-
ble in both cultures of HMEC-1 and HUVEC, regard-
less of heparin used [8].
Heparins also affect the release of TFPI – serine
protease, mainly produced by cells of vascular
endothelium cells, simultaneously being storage of this
inhibitor. The role of TFPI is to inhibit the coagulative
activity of TF/VIIa complex, as well as an inactivation
of factor Xa [9,7]. TFPI is built up of the N-ending
region formed by 3 domains: the first binding VIIa fac-
tor, the second associated with Xa factor and the third,
possessing capability of heparin complexing. The C-
ending fragment plays an extremely significant role in
the anticoagulant activity of TFPI [10,11]. TFPI can be
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Table 2.  Effect of UFH vs LMWHs on anti- and procoagulant fac-
tors in HUVEC culture.
Abbreviation: I. 1-4 hour – incubation in HMEC-1, II. 1-4 hour- incuba-
tion in HUVEC,  III. 24 hour- incubation in HMEC-1 and HUVEC, IV. in
culture of HUVEC, V.  in culture of HMEC-1, HMEC-1 (Human
Microvascular Endothelial Cells), HUVEC (Human Umblical Vein
Endothelial Cells), (+LPS)- after stimulation with  lipopolisaccharide, 
TF – Tissue Factor, TFPI – Tissue Factor Pathway Inhibitor, TM – Throm-
bomodulin, PAI-1 – Plasminogen Activator Inhibitor-1, t-PA – Tissue-type
Plasminogen Inhibitor
found in a free form or a form bound with LDL, the
latter predominating in the plasma. The unbound form
plays the most important role in the anticoagulant
activity of TFPI. It is released from the intracellular
storages upon heparin's stimulation and fulfill as EC
activation/injury indicator [12]. Among the others
Hansen et al. performed studies to confirm TFPI
increase after UFH administration [10]. TFPI concen-
trations in the supernatant from HUVEC culture and
its amount on the surface of culture cells were com-
pared. The significant increase of TFPI concentration
was observed in the fluid fraction but was unchanged
in the HUVEC surface. A hypothesis of heparin's stim-
ulating effect on the release of intracellular TFPI was
put forward [10]. The studies on the differences
between the influence of UFH and LMWHs on the
release of TFPI in vitro proved significant superiority
of LMWH – enoxaparin [7]. The increase in the con-
centration of unbound/free TFPI in HUVEC culture
depended on the incubation time. A significant level
was obtained after 8 hours of enoxaparin application,
whereas during EC stimulation with UFH the
increased release of TFPI was reported after 24 hours
and was lower in comparison with LMWH [7]. West-
mucket's et al. studied two LMWHs: dalteparin and
bemiparin in the culture and confirmed a more potent
effect of LMWHs than UFH on TFPI concentration
[13]. Interesting results were obtained after changing
the infusion conditions (e.g. hydrostatic pressure,
shear stress, flow rate) to get various physiological
types of flows (venous and aortic).  The results were
compared to stimulation with the same heparins in
static conditions. Under the conditions similar to those
in the aortic flow, the TFPI intracellular secretion, its
concentration on the endothelial surface and even its
mRNA expression were significantly higher in case of
bemiparin, whereas UFH and dalteparin had no effect
on these indicators [13]. Similar results were obtained
in the venous flow conditions, which may prove a bet-
ter prevention against thrombin formation under bemi-
parin than during other heparin treatment. Based on
these studies, a modulating influence of blood flow on
the TFPI concentration was proved during heparin
therapy. Similar tests were carried out in HMEC-1 cul-
ture. The concentration of TFPI antigen increased after
UFH and LMWH (dalteparin) administration. Howev-
er, no significant difference was observed between
both heparins [8]. The release of lower amounts of
TFPI after UFH in HUVEC culture is explained by
their greater affinity to this inhibitor. This refers to
both its free and bound forms [7,8]. Hence, LMWHs
administration seems to be much more favorable,
especially in case of arterial thrombosis.  
Thrombomodulin, a protein found on the surface of
endothelium and characterized by anticoagulat proper-
ties, belongs to the markers of EC activation. Heparins
markedly change its plasma concentration, which was
confirmed in HUVEC culture [8].  However, a signifi-
cant increase in TM antigen, regardless the type of
heparin used, being directly proportional to doses
applied, was demonstrated in the study.  Other results
were obtained in HMEC-1 culture, where only LMWH
enhanced TM concentration, whereas UFH had no
influence on this parameter. Preincubation of endothe-
lial cells in HMEC-1 with LPS gave the similar results
– only LMWH modulated TM concentration [8].
The influence of heparins on fibrinolysis has not
been finally explained. Few studies describing this
item demonstrate an increased release of t-PA and PAI-
1 in HUVEC culture after heparins administration. The
significantly high concentration of t-PA was obtained
after stimulation of endothelial cells with UFH, where-
as LMWH (bemiparin) induced its lower increase.
UFH and LMWH increased PAI-1 concentration to
a similar extent. To explain the mechanism responsi-
ble for PAI-1 increase, the expression of its gene was
measured.  However, no differences were proved
between non-stimulated cells and those heparin-treat-
ed. The assumption that there was only a direct influ-
ence of heparins on endothelial cells was confirmed
[6]. The studies were also carried out to discover the
mechanism responsible for the release of   t-PA. They
confirmed its release from endothelial cell and addi-
tionally indicated Weibel-Pallade bodies as the site of
t-PA reservoirs (similarly to vWF) [14, 15].
The hypothesis about more favorable effects of
LMWHs compared to UFH was put forward, based on
haemostatic characteristics of both types of heparins.
The unfavorable activity of UFH was mainly associat-
ed with the stronger activation of endothelium, which
could be demonstrated in an enhanced TF concentra-
tion in the culture [6]. Apart from this, UFH had sig-
nificantly less effect on the release of TFPI than
LMWHs, thus restricting the inhibition of blood coag-
ulation. 
Influence of different heparins on angiogene-
sis in HUVEC culture 
Angiogenesis (forming new vessels from pre-existing
structures) is a process, responsible for the develop-
ment of cancer, which conditions both the growth and
formation of metastases. Migrating endothelial cells
and growth factors such as a vascular endothelial
growth factor (VEGF) or fibroblast growth factor
(FGF) play a key role in this process. 
In recent years, it was demonstrated that heparins
affect angiogenesis, among the others, via inhibition of
growth factors. However, studies carried out in
HUVEC culture proved significant differences
between different heparins in this action.  Cultured
endothelial cells were stimulated by FGF-2 and
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VEGF165 and different heparins: UFH and LMWHs
(6 kDa, 3 kDa, 2.4 kDa, 1.7 Da, 1.2 kDa). Heparin of
medium molecular weight (6 kDa) inhibited the most
effectively cell proliferation and loop formation.
Unfractionated heparins and LMWH (3 kDa) inhibited
angiogenesis to a lesser extent.  No expected results
were observed in the case of lower than 3 kDa frac-
tions [16]. These studies confirmed earlier findings
about the modulating effect of heparan sulphate pro-
teoglycans (HSPG), which are co-receptors responsi-
ble for dimerization of FGF and VEGF and their bind-
ing to a specific receptor on the endothelial cells (and
in this way –  the activation of angiogenesis). Heparins
of molecular weight less than 3 kDa were similar
structurally to sulphates, and therefore they had no
such effects as high-chained heparins that inhibited
growth factors binding to HSPG.
Collen et al. [17] explained that a better antiangio-
genic activity of LMWHs might have a different impact
on the structure and mechanical properties of fibrin that
constituted 'a scaffold' for the development of cancer
and played a main role in the formation of capillary-like
structures. LMWHs enabled the formation of a tight and
fine fibrin net, whereas UFH contributed to the devel-
opment of thick and porous fibers. Based on this study,
the conclusion of more favorable anticancerous effects
during LMWHs therapy was put forward.  However,
taking into consideration the fact that heparins operate
similarly also when fibrin is absent in the culture, this
explanation seems exceptionally inaccurate. Hence, the
explanation demonstrating the influence of heparins on
the receptive mechanism of growth factors activity
seems to be more accurate. 
Marchetti et al. studies [18] also confirmed a more
profitable anticancerous effect of LMWHs in a cell
culture of HMEC-1.  Apart from standard using
recombined VEGF165 and FGF-2, they also applied
agents produced by two different types of neoplastic
cell lines of breast cancer and leukemia. They were the
first to observe not only heparin-induced inhibition of
endothelium proliferation but also the formation of
vascular capillaries caused by these medications. The
studies confirmed explicitly that LMWHs inhibited
markedly better both proliferation and formation of
new vascular loops regardless the type of growth fac-
tors used. The anticancerous activity of LMWHs e.g.,
dalteparin and enoxaparin was compared.  Enoxaparin
appeared to be especially active in the inhibition of
angionenesis induced by growth factors [18]. Addi-
tionally, a main role of VEGF in formation of vessels
was proved. Its concentration was higher in neoplastic
cell culture compared to other released cytokines
(FGF-2, TNF-α) [18]. A modulating effect of heparins
on differentiation and reorganization of cells induced
by an agent coming from neoplasm culture was
demonstrated in these studies.
The mechanism of heparins anticancerous effect
connected with TFPI release from the endothelium
stimulated by LMWH (tinzaparin) and UFH was pre-
sented [19]. It was proved that TF/VIIa complex, sim-
ilarly to FGF-2, activated the formation of new ves-
sels. To confirm the role of TFPI in angiogenesis inhi-
bition, LMWH or a recombined TF inhibitor (rTFPI)
was added to HUVEC culture stimulated by FGF-2 or
TF/VII. The results proved that both LMWH and
rTFPI block the induction of angiogenesis, caused by
both activators. Monoclonal antibodies of TFPI,
applied in the culture, eliminated an early antiangio-
genic effect, which confirmed explicitly the role of
TFPI in inactivation of this process. Tinzaparin was
more efficient than UFH in the inhibition of new ves-
sels formation, which is associated with higher release
of TFPI.
Summing up, low molecular weight heparins,
regardless the anticancerous mechanism (receptor –
type or associated with TFPI release), showed the
higher activity than UFH. Based on the assumption
that cancer requires higher amounts of glucose to its
growth, and its cells are characterized by an increased
expression of glucose transporters (GLUTs), a hypoth-
esis about the possibility of inhibiting these processes
by glucosylated heparins (GH) was  put forward   [20].
The mechanism of anticancerous activity of these
compounds consists in blocking GLUTs. Modified
heparins unable tumor's cells to absorb glucose and
cause their necrosis. It was established simultaneously
that the fewer radicals of glucosamine in the structure
of GH, the more potent effect of proliferation inhibi-
tion in HUVEC.   
Reversely, the anti-Xa activity of these compounds
intensifies itself together with the increased number of
glucosamine radicals, which may decrease the risk of
hemorrhages after administrating more GH. Apart
from this, GH showed no toxic effects on endothelial
cells coming from HUVEC culture [20].
Influence of UFH vs LMWHs on
OPG/RANKL/RANK system
In recent years the interest of many researchers has
been focused on the influence of heparins on the
induction of osteoporosis and initiation of vessels'
calcification connected with atherosclerosis.  These
both mechanisms are related to osteoprotegerin
(OPG), which is a soluble receptor for a RANK lig-
and receptor (RANKL; Receptor Activator of
Nuclear Factor NF-κB Ligand). The role of OPG is
to block the activation of RANK via binding it to its
ligand – RANKL that inhibits osteoclastogenesis – a
loss of bone mass [21].
Heparins, small doses of UFH and big doses of
LMWHs, cause the release of similar amounts of OPG
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from endothelium in HUVEC culture [22]. Additional-
ly, they are able to bind OPG. Especially UFH strong-
ly influences the activation of osteogenesis [23]. C-ter-
minal end region of OPG is responsible for heparins
binding. This discovery has brought us closer to under-
standing the whole mechanism responsible for intensi-
fication of osteoporosis during long-term treatment
with heparins [22]. The examinations performed so far
focused mainly on the role of heparins as activators of
osteoporosis. However, another unexplained problem
is the influence of these drugs on atherogenesis and
vessel calcification via OPG/RANKL/RANK system.
So far, only one finding showing a correlation between
OPG and vWF has been observed [4]. Osteoprotegerin
is physiologically connected with vWF, being at the
same time a well known marker of vessel damage by
means of A1 domain present in its molecule. These
studies proved only the intracellular formation of
vWF-OPG complex. This interaction requires a high
concentration of calcium ions and a low level of chlo-
ride ions and optimum 6.5 pH. Since these conditions
are intracellular, the hypothesis of absence of vWF-
OPG complex in the blood vessels has been presented.
However, up to date, there is no explicit proof con-
firming this thesis. OPG and vWF are probably formed
in the net of the Golgy apparatus and stored as com-
plexes in the Weibel-Pallade bodies [4]. The enhanced
vWF concentration correlated with the extent of dam-
age to endothelium and was one of the thrombosis risk
factors [24]. Despite the certain fact that heparins
cause the activation of endothelial cells, the increased
release of vWF due to their activity has not been
proved. Interestingly, the studies carried out in
HUVEC have shown a decrease in vWF concentration
regardless the type of heparin used [8]. The influence
of heparins on vWF levels in vitro has not been
explained.  There are no findings confirming and
explaining the effect of OPG/RANKL/RANK com-
plex on the development of vessel calcification and its
relation to heparins therapy. Further studies in
HUVEC may help to understand this problem. 
Summary and conclusion
UFH and LMWHs differ significantly in pharmcokinet-
ics, bioaccessibility and in numerous other properties of
great clinical significance. Low-molecular weight
heparins activate endothelial cells to a lesser extent than
UFH. However, they influence more potently to TFPI
release than unfractionated heparins. The profit of
LMWHs therapy is also observed in case of anticancer-
ous mechanisms of heparins.  The inhibition of angio-
genesis induced by growth factors and TF/VIIa complex
is better under LMWHs application. Summing up,
LMWHs predominate over UFH, both with regard to
haemostatic and anticancerous properties, as well as
side effects of their administration.   Another interesting
problem is the influence of various types of heparins on
the OPG/RANKL/RANK system. It is associated with
two different processes: intensified osteoporosis and
heparin effect on vessel calcification associated with
atherosclerosis. Despite many years of studies,
pleiotropic properties of heparins have not been fully
explained and are still in the focus of attention to many
researchers. Studies provided with human vessel cul-
tures may have special significance for the explanation
of heparins' effect on endothelium.
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